Evidence map›Paper›PMID 34622384›Full record

ArticleStem cell reviews and reports2021

Elevated Circulating Stem Cells Level is Observed One Month After Implantation of Carmat Bioprosthetic Total Artificial Heart.

Léa Guyonnet, Grégoire Detriché, Nicolas Gendron, Aurélien Philippe, Christian Latremouille, Lou Soret, Antoine Capel, Christophe Peronino, Piet Jansen, Peter Ivak and 5 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Stem cell reviews and reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Léa Guyonnet *Institut Curie, Cytometry Platform, 75006, Paris, France.
Grégoire Detriché *Innovative Therapies in Haemostasis, INSERM, Université de Paris, 75006, Paris, France.
Nicolas GendronInnovative Therapies in Haemostasis, INSERM, Université de Paris, 75006, Paris, France.
Aurélien PhilippeInnovative Therapies in Haemostasis, INSERM, Université de Paris, 75006, Paris, France.
Christian LatremouilleCarmat SA, Vélizy-Villacoublay, France.
Lou SoretInnovative Therapies in Haemostasis, INSERM, Université de Paris, 75006, Paris, France.
Antoine CapelCarmat SA, Vélizy-Villacoublay, France.
Christophe PeroninoInnovative Therapies in Haemostasis, INSERM, Université de Paris, 75006, Paris, France.
Piet JansenCarmat SA, Vélizy-Villacoublay, France.
Peter IvakDepartment of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Alain CarpentierCardiac Surgery Department and Biosurgical Research Lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, Université de Paris, 75015, Paris, France.
Tristan MiraultVascular Medicine Department and Georges Pompidou European Hospital, AP-HP, 75015, Paris, France.
Ivan NetukaDepartment of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Coralie L GuerinInstitut Curie, Cytometry Platform, 75006, Paris, France.
David M SmadjaInnovative Therapies in Haemostasis, INSERM, Université de Paris, 75006, Paris, France. david.smadja@aphp.fr.
Université Paris Cité · FRAssistance Publique – Hôpitaux de Paris · FRHôpital Européen Georges-Pompidou · FRInserm · FRInstitute of Clinical and Experimental Medicine · CZInstitut Curie · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Aeson® total artificial heart (A-TAH) has been developed as a total heart replacement for patients at risk of death from biventricular failure. We previously described endothelialization of the hybrid membrane inside A-TAH probably at the origin of acquired hemocompatibility. We aimed to quantify vasculogenic stem cells in peripheral blood of patients with long-term A-TAH implantation. Four male adult patients were included in this study. Peripheral blood mononuclear cells were collected before A-TAH implantation (T0) and after implantation at one month (T1), between two and five months (T2), and then between six and twelve months (T3). Supervised analysis of flow cytometry data confirmed the presence of the previously identified Lin

Indexed as

Endothelial CellsHeart, ArtificialAdultAntigens, CD34HumansLeukocytes, MononuclearMaleStem CellsAntigens, CD34AesonEndothelial progenitorsMobilizationStem cellsTotal artificial heartTransplantation

Identifiers

PMID34622384
OpenAlexW3199744343

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.